Match!
Ana De Jesus-Acosta
Johns Hopkins University
OncologyPancreatic cancerAdenocarcinomaRadiation therapyMedicine
44Publications
12H-index
1,406Citations
What is this?
Publications 58
Newest
#1Katherine M. Bever (Johns Hopkins University)H-Index: 5
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 10
Last. Annie A. Wu (Johns Hopkins University)H-Index: 6
view all 21 authors...
Source
#1Ana De Jesus-Acosta (Johns Hopkins University)H-Index: 12
#2Elizabeth A. Sugar (Johns Hopkins University)H-Index: 32
Last. Daniel Laheru (Johns Hopkins University)H-Index: 48
view all 17 authors...
The Hedgehog (Hh) signalling pathway is overexpressed in pancreatic ductal adenocarcinoma (PDA). Preclinical studies have shown that Hh inhibitors reduce pancreatic cancer stem cells (pCSC), stroma and Hh signalling. Patients with previously untreated metastatic PDA were treated with gemcitabine and nab-paclitaxel. Vismodegib was added starting on the second cycle. The primary endpoint was progression-free survival (PFS) as compared with historical controls. Tumour biopsies to assess pCSC, strom...
2 CitationsSource
#1Katherine M. Bever (Johns Hopkins University)H-Index: 5
#2Erkut BorazanciH-Index: 10
Last. Ana De Jesus-Acosta (Johns Hopkins University)H-Index: 12
view all 18 authors...
700Background: Few studies have examined maintenance therapy in unselected pts with metastatic PDA (mPDA). mTOR signaling is central to several oncogenic pathways in PDA and also has a role in T ce...
Source
#1Aurélien Marabelle (French Institute of Health and Medical Research)H-Index: 34
#2Dung T. Le (Johns Hopkins University)H-Index: 36
Last. Luis A. Diaz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 95
view all 22 authors...
PURPOSEGenomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that encode potential ne...
45 CitationsSource
#1Won Jin HoH-Index: 3
#2Ludmila DanilovaH-Index: 29
Last. Mark YarchoanH-Index: 19
view all 11 authors...
Source
#1Thomas Benjamin Karasic (UPenn: University of Pennsylvania)H-Index: 5
#2Mark H. O'Hara (UPenn: University of Pennsylvania)H-Index: 13
Last. Peter J. O'Dwyer (UPenn: University of Pennsylvania)H-Index: 63
view all 14 authors...
Importance Autophagy is a mechanism of treatment resistance to chemotherapy that has a role in the maintenance of pancreatic cancer. Hydroxychloroquine sulfate (HCQ) is an inhibitor of autophagy that inhibits the fusion of the autophagosome to the lysosome. Objective To determine whether HCQ improves overall survival at 1 year in combination with gemcitabine hydrochloride and nab-paclitaxel (GA) among patients with metastatic pancreatic cancer. Design, Setting, and Participants Open-label, phase...
4 CitationsSource
#1Ludmila Danilova (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 29
#2Won Jin Ho (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 4
Last. Mark Yarchoan (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 19
view all 11 authors...
Immune checkpoint therapy has failed to demonstrate meaningful clinical benefit in unselected cases of pancreatic adenocarcinoma (PDAC), but a subset of PDACs are known to upregulate pathways involved in acquired immune suppression. Further delineation of immunologic subtypes of PDAC is necessary to improve clinical trial designs and identify patients who might benefit from immune checkpoint therapy. We employed clinical survival and RNA expression data from The Cancer Genome Atlas (TCGA) to inv...
1 CitationsSource
#1Marina BarettiH-Index: 2
#2Bhargavi PulluriH-Index: 2
Last. Ana De Jesus-AcostaH-Index: 12
view all 11 authors...
ObjectiveLimited data exist on the impact of ascites in pancreatic ductal adenocarcinoma (PDAC). We evaluated the survival outcomes of patients with PDAC and ascites.MethodsRetrospective, single-institution, case-control study including patients with newly diagnosed PDAC from 2007 to 2016. One hundr
1 CitationsSource
#1Mark Yarchoan (Johns Hopkins University)H-Index: 19
#2Anna Ferguson (Johns Hopkins University)H-Index: 9
Last. Nilofer Saba Azad (Johns Hopkins University)H-Index: 27
view all 14 authors...
563Background: Mismatch repair proficient (MMRp) colorectal cancer (CRC) is refractory to single-agent programmed cell death protein 1 (PD1) inhibitors. Cancer vaccines may prime the tumor microenvironment for anti-PD1 therapy. Colon GVAX is an allogeneic, whole-cell, GM-CSF-secreting vaccine that induces T-cell immunity against tumor-associated antigens. GVAX has previously been studied in combination with low-dose cyclophosphamide (Cy) to inhibit regulatory T cells. Methods: We conducted an op...
2 CitationsSource
#1Marina Baretti (Johns Hopkins University)H-Index: 2
#2Qingfeng Zhu (Johns Hopkins University)H-Index: 10
Last. Ana De Jesus-Acosta (Johns Hopkins University)H-Index: 12
view all 6 authors...
267Background: The immune microenvironment in neuroendocrine tumors (NETs) remains largely unexplored with very limited data evaluating its impact on survival. We aimed to characterize the immune microenvironment and lymphocytic infiltrate in patients with gastroenteropancreatic (GEP) NET. Methods: We performed comprehensive immune profiling for CD3, CD8, PD-1, IDO, and PD-L1 expression in two cohorts of patients with primary GEP-NET: patients who had short progression free survival (PFS) ≤ 4 ye...
Source
123456